Anavex Life Sciences Reports Newly Published Data on Alzheimer’s Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor
Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington, DC
5th Annual Mental health Parity Addiction Equity Act Business Roundtable in Washington DC on November 8, 2017
Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2- 73 at 2017 Clinical Trials on Alzheimer’s Disease Meeting
Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference
Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017
